Literature DB >> 30088163

Solid-type poorly differentiated adenocarcinoma of the stomach: clinicopathological and molecular characteristics and histogenesis.

Tomio Arai1, Yoko Matsuda2, Junko Aida3, Kaiyo Takubo3, Toshiyuki Ishiwata3.   

Abstract

BACKGROUND: Despite predominant microsatellite instability (MSI) in intestinal-type gastric carcinomas, we found the most frequent MSI in solid-type poorly differentiated adenocarcinoma (PDA). Although this tumor is classified as PDA, it is hypothesized to possess peculiar features among PDAs. The present study aimed to clarify the clinicopathological and molecular characteristics of this tumor.
METHODS: We examined the expression of p53, mismatch-repair proteins, and mucin core glycoproteins; microsatellite status; and mutations in KRAS and BRAF, as well as clinicopathological features, in 54 cases of PDA of the stomach (31 solid-type PDAs and 23 non-solid-type PDAs).
RESULTS: The proportion (51.6%) of MSI in solid-type PDA was significantly higher than that in non-solid-type PDA (4.5%) (p = 0.00022). The proportion of absent expression of MLH1 (58.1%) and PMS2 (51.6%) in solid-type PDA was significantly higher than that in non-solid-type PDA (4.5 and 8%) (p < 0.0001). No differences were found in the mutations of KRAS and BRAF among PDAs. MSI-positive solid-type PDA was significantly associated with older age, female predominance, lower third location, concordant glandular component, and absent MLH1 and PMS2 expression.
CONCLUSIONS: These results suggest that MSI-positive solid-type PDA has peculiar clinicopathological features and that MSI with absent MLH1 and PMS2 expression may play an important role in tumor development. In addition, from the viewpoint of histogenesis, MSI-positive solid-type PDA may originate from differentiated-type adenocarcinoma.

Entities:  

Keywords:  Elderly; Microsatellite instability; Poorly differentiated adenocarcinoma; Solid carcinoma; Stomach

Mesh:

Substances:

Year:  2018        PMID: 30088163     DOI: 10.1007/s10120-018-0862-6

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  7 in total

1.  Where does signet-ring cell carcinoma come from and where does it go?

Authors:  Tomio Arai
Journal:  Gastric Cancer       Date:  2019-04-08       Impact factor: 7.370

2.  Tumor progression by epithelial-mesenchymal transition in ARID1A- and SMARCA4-aberrant solid-type poorly differentiated gastric adenocarcinoma.

Authors:  Taisuke Sasaki; Kenichi Kohashi; Shinichiro Kawatoko; Eikichi Ihara; Eiji Oki; Masafumi Nakamura; Yoshihiro Ogawa; Yoshinao Oda
Journal:  Virchows Arch       Date:  2022-01-08       Impact factor: 4.064

3.  Microsatellite instability in Chinese gastric cancer and its correlation with clinical characteristics.

Authors:  Xinyu Li; Lan Zhang; Chunxiao Wang; Junli Huang; Jinfeng Zhu; Yisen Huang; Yifeng Chen; Jing Jia; Guozhong Jiang
Journal:  J Gastrointest Oncol       Date:  2021-12

Review 4.  Message in hand: the application of CRISPRi, RNAi, and LncRNA in adenocarcinoma.

Authors:  Ting Wang; Yunhong Yao; Xinrong Hu; Yi Zhao
Journal:  Med Oncol       Date:  2022-07-14       Impact factor: 3.738

5.  Solid-type poorly differentiated adenocarcinoma of the stomach: Deficiency of mismatch repair and SWI/SNF complex.

Authors:  Shinichi Tsuruta; Kenichi Kohashi; Yuichi Yamada; Minako Fujiwara; Yutaka Koga; Eikichi Ihara; Yoshihiro Ogawa; Eiji Oki; Masafumi Nakamura; Yoshinao Oda
Journal:  Cancer Sci       Date:  2020-01-28       Impact factor: 6.716

6.  KRAS status is related to histological phenotype in gastric cancer: results from a large multicentre study.

Authors:  Lindsay C Hewitt; Yuichi Saito; Tan Wang; Yoko Matsuda; Jan Oosting; Arnaldo N S Silva; Hayley L Slaney; Veerle Melotte; Gordon Hutchins; Patrick Tan; Takaki Yoshikawa; Tomio Arai; Heike I Grabsch
Journal:  Gastric Cancer       Date:  2019-05-20       Impact factor: 7.370

7.  A novel nomogram for predicting survival of patients with poorly differentiated gastric adenocarcinoma.

Authors:  Xiaolu Zhou; Zhiyuan Dong; Chenjing Zhang; Xiaoge Geng; Lunan Li; Jiyong Jing; Wensheng Pan; Haifang Lou
Journal:  Transl Cancer Res       Date:  2021-02       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.